Vitalhub (VHI) Planet MicroCap Showcase: VEGAS 2025 summary
Event summary combining transcript, slides, and related documents.
Planet MicroCap Showcase: VEGAS 2025 summary
27 Dec, 2025Company overview and market focus
Specializes in healthcare IT software, with over 50 solutions targeting government-funded healthcare systems outside the U.S., operating in Canada, the U.K., Australia, and the Middle East.
Growth achieved through both organic means and 22 acquisitions, reaching over $70 million in annual recurring revenue (ARR).
Focuses on consolidating niche vendors to create a stronger, cohesive offering in a $10 billion non-U.S. healthcare IT market.
Product and solution portfolio
Main offerings include patient flow and operational visibility solutions, helping healthcare organizations manage patient movement and capacity.
Patient engagement products assist individuals with navigation, scheduling, and aftercare within healthcare systems.
Electronic records for social services and care coordination, primarily in Canada, serve large organizations and entire provinces.
Workforce automation solutions, mainly in the U.K., support compliance, recruiting, and certification for healthcare staff.
M&A and operational strategy
Acquisitions target companies with $2–$20 million in revenue, focusing on those with at least 60% recurring revenue.
Typical acquisition multiples range from 1x to 2.5x revenue, with some exceptions above 3x.
Integration strategy includes consolidating G&A, leveraging a 200+ person Sri Lankan R&D team for cost-effective innovation.
Cross-selling and operational synergies drive organic ARR growth, averaging $1.5 million per quarter.
Latest events from Vitalhub
- Q3 revenue and ARR up 25%, pro forma ARR hits CAD 68M after acquisitions, cash at CAD 81.4M.VHI
Q3 202411 May 2026 - ARR up 54% and revenue up 42%, with CAD 91.2M cash fueling strong M&A activity.VHI
Q1 202511 May 2026 - ARR and revenue surged year-over-year, margins improved, and cash reserves strengthened.VHI
Q1 202611 May 2026 - ARR and revenue surged in 2025, with robust EBITDA growth and strong cash for acquisitions.VHI
Q4 20254 May 2026 - Q2 revenue up 24% with 41% higher adjusted EBITDA and MedCurrent acquisition pending.VHI
Q2 20241 Feb 2026 - Growth through acquisitions and AI integration aims to boost recurring revenue and margins by 2026.VHI
2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026 - Delivers $93.7M ARR and 22% EBITDA margin through global healthcare software and M&A.VHI
Investor presentation15 Jan 2026 - ARR up 59% and revenue up 31% in 2024, with robust M&A and strong cash position.VHI
Q4 202426 Dec 2025 - ARR up 55%, revenue up 47%, 26% EBITDA margin, and strong acquisition integration.VHI
Q2 202523 Nov 2025